Bottom line
Switching GLP-1s is straightforward — most transitions don't require a washout period because the drugs share the same core mechanism. The exact protocol depends on which two drugs you're moving between and whether the switch is for efficacy, tolerability, cost, or insurance reasons.
This guide covers the five most common switches in 2026:
- Wegovy → Zepbound (efficacy)
- Ozempic → Wegovy (indication alignment)
- Zepbound → Wegovy (CV indication, insurance)
- Injection → Wegovy Pill (preference, needle aversion)
- Brand → Compounded or back (cost, quality)
Wegovy → Zepbound {#wegovy-to-zepbound}
The most common switch. Typical reasons: plateau below goal, higher efficacy sought (SURMOUNT-5 showed tirzepatide produced 47% more weight loss than semaglutide), insurance preference change, or better GI tolerability of tirzepatide at similar efficacy.
Typical protocol: 1. Take last Wegovy dose on schedule. 2. Wait 1 week (skip the next Wegovy injection). 3. Start Zepbound 2.5 mg. 4. Titrate normally: 2.5 → 5 mg at 4 weeks, then by 2.5 mg every 4 weeks as tolerated to target (10 or 15 mg).
No washout longer than 1 week is typically needed because both drugs are GLP-1-class and steady-state concentrations clear within a few half-lives.
Some prescribers skip the washout and go directly from Wegovy's injection day to Zepbound 2.5 mg one week later — effectively replacing the next Wegovy dose with Zepbound.
What to expect: mild GI recurrence at 2.5 mg is normal as your body adjusts to the dual GIP/GLP-1 mechanism versus GLP-1 alone. Often resolves by week 2–3.
Ozempic → Wegovy {#ozempic-to-wegovy}
The second most common switch. Typical reason: on Ozempic off-label for weight loss and want the full 2.4 mg dose with on-label insurance coverage.
Typical protocol:
- On Ozempic 0.5 mg → switch to Wegovy 0.5 mg same week.
- On Ozempic 1.0 mg → switch to Wegovy 1.0 mg same week.
- On Ozempic 2.0 mg → switch to Wegovy 1.7 mg for 4 weeks, then
Wegovy 2.4 mg.
Same molecule at corresponding doses — no washout, no titration restart. The higher doses (Wegovy 2.4 mg doesn't have an Ozempic equivalent) require a brief step-up.
What to expect: minimal change in side effects at matched doses. Patients moving from Ozempic 2.0 mg to Wegovy 2.4 mg sometimes see slightly more nausea at the higher dose.
Zepbound → Wegovy {#zepbound-to-wegovy}
Less common but real reasons: established cardiovascular disease wanting Wegovy's SELECT evidence, insurance carrier changed preferred formulary, unmanageable GI side effects at Zepbound doses.
Typical protocol: 1. Last Zepbound dose on schedule. 2. Wait 1 week. 3. Start Wegovy at 1.7 mg (if coming from Zepbound 7.5–10 mg) or at 1.0 mg (if coming from Zepbound 2.5–5 mg). 4. Escalate to 2.4 mg after 4 weeks.
What to expect: expect modestly less weight loss over time. Stopping tirzepatide often reveals how much of your response came from the GIP receptor activity semaglutide doesn't cover.
Injection → Wegovy Pill {#injection-to-pill}
Reasons: needle aversion, travel frequency, preference for oral.
Typical protocol from Wegovy injection:
- From Wegovy 1.7 mg → Wegovy Pill 14 mg daily for 4 weeks →
25 mg daily.
- From Wegovy 2.4 mg → Wegovy Pill 25 mg daily (direct, though
some prescribers do a 14 mg transition week).
Typical protocol from Zepbound injection: there's no direct tirzepatide-to-pill path, so the transition is molecular. Usually:
- Zepbound 5–7.5 mg → Wegovy Pill 14 mg for 4 weeks → 25 mg.
- Zepbound 10–15 mg → Wegovy Pill 14 mg for 4 weeks → 25 mg,
with the expectation that efficacy will be lower than at Zepbound maintenance.
What to expect: expect some loss of efficacy when moving off tirzepatide. The pill's strict fasting protocol is a real adherence challenge — read the Wegovy Pill page before switching.
Brand → Compounded or back {#brand-to-compounded}
With identical-molecule tirzepatide and semaglutide compounding largely ended after FDA shortage-list removal in 2024–2025, most "compounded" alternatives in 2026 are non-identical analogs of uncertain equivalence.
Typical reasons to switch TO compounded:
- Insurance dropped brand coverage
- Cannot afford brand cash price
- Privacy / off-grid preference
Typical reasons to switch BACK to brand:
- Insurance now covers brand
- Concerns about compounded analog quality
- Clinical team advises standardization
Protocol: at equivalent doses, compounded → brand switches are immediate with no washout. Brand → compounded analog switches may produce different tolerability since the molecules aren't identical.
If you're considering compounded, read insurance coverage in 2026 first — you may have coverage options you haven't exhausted.
What every switch has in common
- No washout longer than 1 week for same-class switches.
- Dose matching by pharmacokinetic equivalence, not by brand label.
- Brief GI side effect recurrence at the new drug's first dose.
- Insurance PA may need to be re-run for the new drug.
- Pen/supplies change — don't pre-order the next month until
you're sure the switch is happening.
Most GLP-1 switches work. The ones that fail are usually switches back to old-generation drugs (e.g., Wegovy → Saxenda), where the efficacy drop makes the change not worth it.
See the Sherpa Matcher if you're not sure which drug fits your current situation better.